Innova Biosciences and Cancer Research Technology (CRT), the commercialisation arm of Cancer Research UK, have signed a licence agreement to develop a portfolio of conjugated antibodies against novel oncology targets.
Innova specialises in bioconjugation, the joining of two molecules to form hybrid conjugates, for use in diagnostic tests. Innova has developed a one-step conjugation method, Lightning-Link, which is much faster and easier to perform than existing techniques
Under the deal, Innova will generate a collection of novel antibody research tools for the research community. Cancer Research UK funds 4,500 researchers in the UK.